comparemela.com

Nammi Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Local Companies and Research Institutes at Forefront of Cancer Immunotherapy Development

Learn more about several local companies and research institutions that are at the forefront of targeted immunotherapy research and drug development

National institutes of healthUnited statesCulver cityThousand oaksCarlton southLos angeles countySanta monicaNoord hollandDavid stoverStephen formanStephanie hsiehRingo chiu stoverFrank neumannAntoni ribasLos angelesDavid storer

Nammi s Cancer Immunotherapy Technology Garners Award and Stem Cell Grant

Learn more about Westwood-based Nammi Therapeutics’ cancer immunotherapy technology and the recent award and $4 million grant it has garnered.

United statesSanta monicaDavid stoverStephanie hsiehSherie morrisonJandre nelRingo chiu david stoverAmgen biolabsGeorge ayoubSan california institute of regenerative medicineDrug administrationAstellas pharma incTerasaki institute for biomedical innovationCalifornia stem cell agencyAmgen incLundquist institute

AMGEN AND BIOLABS LA AT THE LUNDQUIST INSTITUTE ANNOUNCE NAMMI THERAPEUTICS TO RECEIVE THE THIRD AMGEN GOLDEN TICKET

/PRNewswire/ Amgen (NASDAQ:AMGN) and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden.

United statesThousand oaksSan franciscoMichael strapazonLos angelesAlan russellDavidr stoverKeithb hoffmanBiotherapeutics company toLundquist institute for biomedical innovationMost sustainable companiesResearch labLundquist instituteNammi therapeutics incNammi therapeuticsAmgen golden ticket

Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Pancreatic Cancer

/PRNewswire/ Nammi Therapeutics, Inc. (Nammi), a Los Angeles based immunotherapy company, announced today that the US Food and Drug Administration (FDA) has.

United statesLos angelesDrug administrationNammi therapeutics incPrnewswire nammi therapeutics incAmerican cancer societyMasked immunocytokinePancreatic cancerInvestigational new drugNammi therapeuticsImmune modulating prodrugsHealth care amp hospitals

Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Multiple Myeloma

/PRNewswire/ Nammi Therapeutics, Inc. (Nammi), an LA-based immunotherapy company, announced today that the US Food and Drug Administration (FDA) has granted.

United statesLos angelesDrug administrationNammi therapeutics incPrnewswire nammi therapeutics incAmerican cancer societyMasked immunocytokineInvestigational new drugNammi therapeuticsImmune modulating prodrugsHealth care amp hospitalsMedical pharmaceuticalsFda approval

vimarsana © 2020. All Rights Reserved.